STOCK TITAN

InflaRx N.V. (IFRX) Stock Price, News & Analysis

IFRX NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
66 252 sessions, November 20, 2025 to November 20, 2026
Largest daily move
+32.5% close of April 17, 2026
1-year change
-9.6% closing prices, November 20, 2025 to November 20, 2026
1-month change
-32.5% closing prices, October 20, 2026 to November 20, 2026

Company Description

InflaRx N.V. (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused on anti-inflammatory therapeutics that target the complement system, specifically the complement activation factor C5a and its receptor, C5aR. According to company disclosures, C5a is described as a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx applies proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of this pathway.

InflaRx was founded in 2007. The group reports offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, Michigan, USA. InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. The company’s ordinary shares trade on Nasdaq under the ticker symbol IFRX.

Therapeutic focus and technology platform

InflaRx states that it is pioneering anti-inflammatory therapeutics by targeting C5a and C5aR. Its programs are designed to inhibit C5a-induced signaling while leaving the formation of the membrane attack complex (C5b-9) intact as part of the innate immune defense. The company highlights its proprietary anti-C5a monoclonal antibody technology and small-molecule C5a receptor inhibition as the core of its research and development efforts.

The company’s disclosures describe two main product candidates within this complement-focused platform: vilobelimab, an intravenously delivered monoclonal antibody against C5a, and izicopan (also referenced as INF904), an orally administered small molecule inhibitor of C5a-induced signaling via the C5a receptor. Both programs are positioned by InflaRx as highly specific inhibitors of the C5a/C5aR axis.

Izicopan (INF904): oral C5aR inhibitor

InflaRx describes izicopan (INF904) as an orally administered, small molecule inhibitor of the C5a receptor (C5aR1) that has shown anti-inflammatory therapeutic effects in several pre-clinical disease models and in human studies. Company materials report that pharmacokinetic and pharmacodynamic data support what InflaRx characterizes as best-in-class potential, with a high degree of blockade of C5a-induced neutrophil activation over a multi-day dosing period.

According to InflaRx, izicopan has been evaluated in a first-in-human study and in a Phase 2a basket study in patients with hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU). The company reports that in these studies, izicopan was well tolerated and that no safety signals of concern were observed across the dosing ranges studied. InflaRx also reports that Phase 2a data in HS showed rapid and clinically meaningful reductions in abscesses and nodules and draining tunnels, improvements in HS clinical response measures, and reductions in patient-reported pain scores over a four-week treatment period, with responses that continued to deepen during a subsequent off-treatment observation period.

In CSU, InflaRx reports that Phase 2a data showed substantial reductions in the 7-day Urticaria Activity Score (UAS7), particularly in patients with severe disease at baseline, as well as improved disease control as measured by the Urticaria Control Test (UCT7). The company states that the level of activity observed in its analyses exceeded average historically reported placebo levels and was generally within the range of existing approved CSU therapies, while emphasizing that these comparisons are based on separate studies and are not derived from head-to-head trials.

Company communications describe izicopan as having characteristics that support its exploration across multiple inflammation and immunology (I&I) indications, including HS and CSU, and refer to it as a potential “pipeline-in-a-product” within the C5aR inhibitor class.

Vilobelimab and GOHIBIC (vilobelimab)

InflaRx reports that it has developed vilobelimab, a novel, intravenously delivered, first-in-class anti-C5a monoclonal antibody. The antibody is described as selectively binding to free C5a and effectively blocking its biological activity, while leaving formation of the membrane attack complex intact. Company disclosures state that vilobelimab has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies.

InflaRx also refers to GOHIBIC (vilobelimab) in its communications. The company reports that GOHIBIC (vilobelimab) is approved in the European Union under exceptional circumstances for the treatment of adults with SARS-CoV-2-induced acute respiratory distress syndrome (ARDS) who are receiving systemic corticosteroids as part of standard of care and receiving invasive mechanical ventilation with or without extracorporeal membrane oxygenation. InflaRx further notes that GOHIBIC (vilobelimab) is the first treatment approved in the EU for SARS-CoV-2-induced ARDS under these conditions.

Beyond ARDS, InflaRx has reported clinical development of vilobelimab in other indications. Company updates describe a Phase 3 trial in pyoderma gangrenosum (PG) that was stopped early for futility with respect to its prespecified primary endpoint, followed by post-hoc analyses that, according to the company, suggested signals of efficacy in ulcer volume reduction and related measures. InflaRx has indicated that it anticipates discussions with the U.S. Food and Drug Administration (FDA) regarding a potential development path forward in PG, and that any further development in this indication would likely be pursued in collaboration with a partner.

Strategic focus and pipeline prioritization

In recent communications, InflaRx has outlined a strategy focused on what it characterizes as capital-efficient execution and near-term value creation centered on izicopan. The company has announced that it intends to prioritize izicopan as its leading pipeline asset, with a goal of progressing toward Phase 2b readiness in hidradenitis suppurativa and broadening signal-finding activities in additional inflammation and immunology indications.

To support this focus, InflaRx has reported measures to reduce spending and streamline its organizational structure, including a workforce reduction and substantial reductions in commercial spending related to GOHIBIC (vilobelimab). The company states that it plans to maintain the operational capability needed to support ongoing clinical work, including a BARDA-funded Phase 2 platform study in ARDS, and to keep GOHIBIC (vilobelimab) available for ordering in the United States under its emergency use authorization on what it describes as a reactive basis.

InflaRx also reports that it is engaged in ongoing discussions with potential collaborators to support development of izicopan across HS, CSU and other I&I indications, and that it continues to evaluate partnering opportunities for vilobelimab and GOHIBIC in various geographies. The company has additionally highlighted a co-development agreement in China under which a partner is developing an anti-C5a antibody (BDB-001) based on the vilobelimab cell line, with InflaRx entitled to receive royalties on net sales of products containing BDB-001.

Regulatory and listing status

InflaRx files reports with the U.S. Securities and Exchange Commission as a foreign private issuer on Form 20-F and Form 6-K. The company’s SEC filings include financial statements, management’s discussion and analysis of financial condition and results of operations, and updates on clinical and corporate developments.

In 2025, InflaRx reported that it had received a notice from Nasdaq regarding non-compliance with the minimum bid price requirement and an associated compliance period. The company later disclosed that it had received written notice from Nasdaq indicating that it had regained compliance with the minimum bid price requirement after its ordinary shares closed at or above the required threshold for the specified number of consecutive business days. These notices, as described in the company’s Form 6-K filings, did not have an immediate effect on the listing or trading of the company’s ordinary shares.

Geographic footprint and corporate structure

InflaRx describes itself as having offices and subsidiaries in Germany and the United States. The group’s presence includes Jena and Munich in Germany and Ann Arbor in the United States. InflaRx GmbH and InflaRx Pharmaceuticals Inc. are identified as wholly owned subsidiaries of InflaRx N.V. This structure supports the company’s research, development and corporate activities related to its complement-focused biopharmaceutical programs.

Business model characteristics

Based on its public disclosures, InflaRx operates as a clinical-stage biopharmaceutical company. Its activities are centered on the discovery, development and potential commercialization of therapies that inhibit C5a and C5aR in inflammatory and autoimmune conditions. The company’s revenue disclosures indicate that, to date, revenues have been primarily related to GOHIBIC (vilobelimab) sales, while a substantial portion of expenses relates to research and development, sales and marketing, and general and administrative activities associated with its pipeline and commercial efforts.

InflaRx’s communications emphasize continued investment in clinical trials for izicopan and vilobelimab, regulatory interactions, and potential collaborations or partnerships to advance its programs and, where applicable, to support commercialization in selected markets.

Key programs and indications mentioned by the company

  • Izicopan (INF904): Oral C5aR inhibitor under development, with Phase 2a data reported in hidradenitis suppurativa and chronic spontaneous urticaria and plans described by the company to progress toward Phase 2b development in HS and further exploration in CSU and other I&I indications.
  • Vilobelimab / GOHIBIC (vilobelimab): Intravenous anti-C5a monoclonal antibody that has been evaluated in multiple clinical settings, including ARDS and pyoderma gangrenosum, with GOHIBIC (vilobelimab) approved in the European Union under exceptional circumstances for adults with SARS-CoV-2-induced ARDS who meet specified treatment criteria.
  • Collaborative programs: Anti-C5a antibody BDB-001 being developed by a partner in China using the vilobelimab cell line, with InflaRx entitled to royalties on net sales of BDB-001-containing products.

Risk and regulatory considerations

InflaRx’s press releases and SEC filings include forward-looking statements that outline risks and uncertainties related to clinical development, regulatory approvals or authorizations, manufacturing, commercialization, financing, and competitive dynamics in the field of C5a and C5aR inhibitors. The company refers readers to the “Risk Factors” section of its periodic SEC filings for a more detailed discussion of these risks.

Stock Performance

$1.02
-1.92%
-0.02
After hoursChange vs the $1.04 closeLast updated: at
-9.6%
Performance 1 year
$150.3M

InflaRx N.V. (IFRX) closed at $1.04 on November 20, 2026. Over the past 12 months, the price has lost 9.6%.

See what a $1,000 investment in IFRX would be worth today

Average down calculator for IFRX

IFRX Metrics & Rankings

Price returns through November 20, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Financial Highlights

InflaRx N.V. generated $34K in revenue in FY2025, and net income was -$53.6M. Diluted earnings per share stood at -$0.80. The company generated -$41.4M in operating cash flow. The current ratio was 4.13, measuring current assets divided by current liabilities.

$34K
Revenue (FY2025)
-$53.6M
Net Income (FY2025)
-$41.4M
Operating Cash Flow
-$8.5M
Gross Profit (FY2025)

Upcoming Events

YEAR
2027
2027 Clinical

AAV Phase 2 start

Site initiation expected early 2027 for randomized Phase 2 AAV trial testing two izicopan doses vs placebo alongside standard care.
YEAR
2027
2027 Clinical

Open-label AAV study

Open-label study expected in early 2027 to explore replacing glucocorticoids during izicopan treatment to induce remission.
YEAR
2027
2027 Clinical

IgA nephropathy pilot

IgA nephropathy pilot planned for 2027 to evaluate izicopan; early data are anticipated to follow in 2028.
YEAR
2027
2027 Clinical

Open-label renal data readout

Open-label renal study data expected in 2027; readouts for aHUS, IgAN, C3G; timing and sites to be announced.
YEAR
2027
2027 Clinical

Initial renal data

Initial renal proof-of-concept data for izicopan targeted for 2027 across aHUS, IgAN and C3G; topline timing and presentation TBD.
H2
2027
H2 2027 Clinical

aHUS study data

Initial data from investigator-initiated atypical hemolytic uremic syndrome (aHUS) study expected in the second half of 2027.
YEAR
2028
2028 Clinical

AAV Phase 2 data

First data anticipated in 2028 from randomized Phase 2 AAV trials of izicopan (two doses vs placebo) with kidney involvement focus.
YEAR
2028
2028 Clinical

IgA pilot data

Early data expected in 2028 from the IgA nephropathy pilot assessing izicopan; potential early safety and efficacy readouts.

InflaRx N.V. has 8 upcoming scheduled events. The next event, "AAV Phase 2 start", is expected in 2027. Investors can track these dates to stay informed about potential catalysts that may affect the IFRX stock price.

Short Interest History

Last 12 Months

Short interest in InflaRx N.V. (IFRX) currently stands at 12.8 million shares, up 0.9% from the previous reporting period, representing 9.0% of the float. Since November 2025, short interest has increased by 492.8%.

Days to Cover History

Last 12 Months

Days to cover for InflaRx N.V. (IFRX) currently stands at 15.0 days, down 30.9% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 518.1%. Across the settlements charted above, it has ranged from 1.0 to 26.6 days.

IFRX Company Profile & Sector Positioning

InflaRx N.V. (IFRX) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing IFRX often look at related companies in the same sector, including Palisade Bio, Inc. (PALI), ProQR Therapeutics N.V. (PRQR), Sutro Biopharma, Inc. (STRO), Compugen Ltd (CGEN), and Oramed Pharmaceuticals Inc. (ORMP). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate IFRX's relative position within its industry.

Frequently Asked Questions

The current stock price of InflaRx N.V. (IFRX) is $1.02 in after-hours trading as of November 20, 2026.

The market cap of InflaRx N.V. (IFRX) is approximately $150.3M. Learn more about what market capitalization means .

The FY2025 revenue of InflaRx N.V. (IFRX) is $34K, from its most recent completed fiscal year.

The FY2025 net income of InflaRx N.V. (IFRX) is -$53.6M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of InflaRx N.V. (IFRX) is -$0.80 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of InflaRx N.V. (IFRX) is -$41.4M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The current ratio of InflaRx N.V. (IFRX), current assets divided by current liabilities, was 4.13 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The gross profit of InflaRx N.V. (IFRX) is -$8.5M for FY2025, its most recent completed fiscal year.

InflaRx N.V. focuses on discovering, developing and commercializing anti-inflammatory therapeutics that target the complement system, specifically the complement activation factor C5a and its receptor C5aR. The company applies proprietary anti-C5a and anti-C5aR technologies to develop highly potent and specific inhibitors for inflammatory diseases.

InflaRx reports two key programs: vilobelimab, an intravenously delivered anti-C5a monoclonal antibody that selectively binds free C5a, and izicopan (also referenced as INF904), an orally administered small molecule inhibitor of C5a-induced signaling via the C5a receptor. Both are intended to modulate the C5a/C5aR axis in inflammatory conditions.

Company disclosures state that izicopan has been evaluated in a Phase 2a basket study in hidradenitis suppurativa and chronic spontaneous urticaria. InflaRx has described plans to progress toward Phase 2b readiness in hidradenitis suppurativa and to explore further development in chronic spontaneous urticaria and other inflammation and immunology indications.

GOHIBIC (vilobelimab) is the name used by InflaRx for vilobelimab in its approved indication in the European Union. The company states that GOHIBIC (vilobelimab) is approved in the EU under exceptional circumstances for adults with SARS-CoV-2-induced acute respiratory distress syndrome who are receiving systemic corticosteroids as part of standard of care and invasive mechanical ventilation with or without extracorporeal membrane oxygenation.

InflaRx describes vilobelimab as a first-in-class monoclonal anti-human complement factor C5a antibody that highly and effectively blocks the biological activity of C5a while leaving formation of the membrane attack complex (C5b-9) intact. This approach is intended to control inflammatory response-driven tissue and organ damage by specifically blocking C5a.

InflaRx reports that it was founded in 2007 and that the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, Michigan, USA. InflaRx GmbH and InflaRx Pharmaceuticals Inc. are wholly owned subsidiaries of InflaRx N.V.

InflaRx states that its ordinary shares are listed on Nasdaq under the ticker symbol IFRX. As a foreign private issuer, the company files annual reports on Form 20-F and current reports on Form 6-K with the U.S. Securities and Exchange Commission.

InflaRx has communicated a strategy to prioritize izicopan as its leading pipeline asset, focusing resources on its development in hidradenitis suppurativa and other inflammation and immunology indications. The company has also reported spending reductions, a workforce reduction and lower commercial spending related to GOHIBIC (vilobelimab) to extend its cash runway and align resources with this focus.

InflaRx issues press releases and files reports on Form 6-K and Form 20-F with the U.S. Securities and Exchange Commission. These documents provide details on clinical trial outcomes, regulatory interactions, financial results and other corporate developments related to its programs.